Department of Surgery »  Faculty »  Adult Cardiothoracic Surgery »  Johannes R. Kratz, M.D.
Johannes R. Kratz, M.D.

Johannes R. Kratz, M.D.

Assistant Professor of Surgery
Division of Adult Cardiothoracic Surgery
Director, Advanced Minimally Invasive Thoracic Surgery



Contact Information

Open Popup
  • M.D. Harvard Medical School, Boston, MA., Magna cum laude, 2006
  • M.A. Stanford University, Palo Alto, CA., Philosophy, 2000
  • B.S. Stanford University, Palo Alto, CA., Biological Sciences (with Honors with Distinction), 1999
  • B.A. Stanford University, Palo Alto, CA.,Philosophy (with Distinction), 1999
  • 6/06-6/14 Resident, Department of General Surgery. Massachusetts General Hospital, Boston, MA.
  • ACGME Fellowship in Thoracic Surgery, UCSF, 2014-2017
  • Surgical Robotics Fellowship, American Association of Thoracic Surgery Graham Foundation, Beverly, MA 2015 - 2016
  • Advanced Surgical Robotics Fellowship, University of Alabama, Birmingham (Dr. Cerfolio), 2016
  • Research Fellow, Thoracic Oncology Laboratory, University of California, San Francisco, 2008-2011
  • Research in Vascular Biology, Dr. Guillermo Garcia-Cardena, Brigham and Women's Hospital, Harvard Medical School, Boston, CA
  • American Board of Surgery
  • Inflammation in lung tumorigenesis
  • Molecularly-targeted cancer therapies
  • Prognostic assays for early stage lung cancer

Johannes R. Kratz, M.D. is a thoracic surgeon in the Division of Adult Cardiothoracic Surgery and Thoracic Oncology Program. Dr. Kratz received his M.D. from Harvard Medical School, graduating Magna cum laude in 2006. He also holds a Masters in Philosophy from Stanford where he did his undergraduate work. 

Dr. Kratz worked as research fellow in the Thoracic Oncology Lab from 2008-2011 where he played a pivotal role in the development of a prognostic assay for early-stage lung cancer patients, reported on in The Lancet and JAMA. The novel assay was validated in an international clinical trial led by thoracic surgeons David M. Jablons, M.D. and Michael Mann, M.D. The assay better predicted risk of death in early-stage lung cancer patients versus conventional staging guidelines and later successfully identified Stage 1A lung cancer patients who had a very high likelihood of mortality after surgery. Dr. Kratz finished his clinical training as a clinical fellow in Thoracic Surgery at UCSF from 2014-2017.

Dr. Kratz has published numerous papers and has been the recipient of numerous awards and honors including the Partners Healthcare Resident/Fellow as Teacher Award, Willard M. Daggett Award, Edward Churchill Surgical Research Fellowship, Wyeth Scholarship of the American College of Surgeons, John E. Thayer Scholarship Award, Howard Hughes Medical Fellows Program Continued Support Award, Howard Hughes Medical Student Research Fellowship, and designation as a Soma Weiss Scholar.

Dr. Kratz was recently honored with the 2017 UCSF Health Exceptional Physician Award for service during the last year of his clinical fellowship, among 8 winners out of 61 nominees, notably the only clinical fellow at UCSF to receive the award in 2017, and one of only two winners not on the faculty.

Most recent publications from a total of 21
  1. Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 May 31. View in PubMed
  2. Kratz JR, Woodard G, Jablons DM. Management of Lung Cancer Invading the Superior Sulcus. Thorac Surg Clin. 2017 May; 27(2):149-157. View in PubMed
  3. Shah JA, Patel MS, Kratz JR, Markmann JF, Vagefi PA.  High risk, high reward: An analysis of outcomes for candidates awaiting hepatic re-transplantation. Ann Hepatol. 2016 Nov-Dec 2016; 15(6):888-894. View in PubMed
  4. Hirata T, Zheng Q, Chen Z, Kinoshita H, Okamoto J, Kratz J, Li H, Lui N, Do H, Cheng T, Tseng HH, Koizumi K, Shimizu K, Zhou HM, Jablons D, He B. Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma. Oncol Rep. 2015 Apr; 33(4):2052-60. View in PubMed
  5. Patel MS, Kohn R, Kratz JR, Shah JA, Markmann JF, Vagefi PA. The race to liver transplantation: a comparison of patients with and without hepatocellular carcinoma from listing to post-transplantation. J Am Coll Surg. 2015 Jun; 220(6):1001-7. View in PubMed
  6. Kohn R, Kratz JR, Markmann JF, Vagefi PA. The migrated liver transplantation candidate: insight into geographic disparities in liver distribution. J Am Coll Surg. 2014 Jun; 218(6):1113-8. View in PubMed
  7. Kratz JR, Tham PT, Mulvihill MS, Ziaei F, Ray MR, Hurst JW, Segal MR, Berryman DM, Chu W, He B, Jablons DM, Mann MJ. Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer. Diagn Mol Pathol. 2013 Jun; 22(2):65-9. View in PubMed
  8. Kratz JR, Mann MJ, Jablons DM. International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature. Transl Lung Cancer Res. 2013 Jun; 2(3):222-5. View in PubMed
  9. Mann MJ, Jablons DM, Kratz JR. Prognostic assay in small, node-negative non-small cell lung cancer--reply. JAMA. 2013 Feb 27; 309(8):769-70. View in PubMed
  10. Mulvihill MS, Kratz JR, Pham P, Jablons DM, He B. The role of stem cells in airway repair: implications for the origins of lung cancer. Chin J Cancer. 2013 Feb; 32(2):71-4. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Johannes R. Kratz, M.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X